Topics

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

08:10 EST 8 Jan 2020 | InvestorIdeas

January 8, 2020 (Investorideas.com Newswire) Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria.

Original Article: Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

NEXT ARTICLE

More From BioPortfolio on "Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...